CA2622916A1 - Procede d'obtention de cellules musculaires lisses humaines et leurs applications - Google Patents

Procede d'obtention de cellules musculaires lisses humaines et leurs applications Download PDF

Info

Publication number
CA2622916A1
CA2622916A1 CA002622916A CA2622916A CA2622916A1 CA 2622916 A1 CA2622916 A1 CA 2622916A1 CA 002622916 A CA002622916 A CA 002622916A CA 2622916 A CA2622916 A CA 2622916A CA 2622916 A1 CA2622916 A1 CA 2622916A1
Authority
CA
Canada
Prior art keywords
cells
muscle
medium
human
biopsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002622916A
Other languages
English (en)
French (fr)
Inventor
Sophie Le Ricousse
Marie-Noelle Lacassagne
Jean-Pierre Marolleau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
IVS Institut des Vaisseaux et du Sang
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2622916A1 publication Critical patent/CA2622916A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0661—Smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
CA002622916A 2005-09-19 2006-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications Abandoned CA2622916A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0509557A FR2890977A1 (fr) 2005-09-19 2005-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications
FR0509557 2005-09-19
PCT/FR2006/002144 WO2007034069A1 (fr) 2005-09-19 2006-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications

Publications (1)

Publication Number Publication Date
CA2622916A1 true CA2622916A1 (fr) 2007-03-29

Family

ID=36587333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002622916A Abandoned CA2622916A1 (fr) 2005-09-19 2006-09-19 Procede d'obtention de cellules musculaires lisses humaines et leurs applications

Country Status (10)

Country Link
US (1) US20090269310A1 (https=)
EP (1) EP1934333B9 (https=)
JP (1) JP2009508511A (https=)
CN (1) CN101310013B (https=)
AT (1) ATE531791T1 (https=)
AU (1) AU2006293814B2 (https=)
CA (1) CA2622916A1 (https=)
FR (1) FR2890977A1 (https=)
IL (1) IL190289A0 (https=)
WO (1) WO2007034069A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
ES2689932T3 (es) * 2008-11-04 2018-11-16 Inregen Construcciones de armazones de células
US11617768B2 (en) * 2017-12-14 2023-04-04 Innovacell Ag Methods for obtaining muscle derived cells
CN112119155A (zh) * 2018-05-08 2020-12-22 苏黎士大学 用于无异种产生hMPC群的方法
IL286509B1 (en) * 2019-03-22 2026-04-01 Innovacell Gmbh Methods for obtaining induced smooth muscle cells
WO2024143453A1 (ja) * 2022-12-28 2024-07-04 インターステム株式会社 細胞組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
US20040247575A1 (en) * 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells

Also Published As

Publication number Publication date
US20090269310A1 (en) 2009-10-29
FR2890977A1 (fr) 2007-03-23
CN101310013B (zh) 2011-09-07
IL190289A0 (en) 2011-08-01
AU2006293814A1 (en) 2007-03-29
AU2006293814B2 (en) 2011-09-29
EP1934333B1 (fr) 2011-11-02
EP1934333B9 (fr) 2012-05-02
EP1934333A1 (fr) 2008-06-25
JP2009508511A (ja) 2009-03-05
ATE531791T1 (de) 2011-11-15
WO2007034069A1 (fr) 2007-03-29
CN101310013A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
Alviano et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro
Wassmer et al. Bio-engineering of pre-vascularized islet organoids for the treatment of type 1 diabetes
Leri et al. Cardiac stem cells and mechanisms of myocardial regeneration
EP1349919B1 (fr) Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution du tissu cardiaque
Sieveking et al. Cell therapies for therapeutic angiogenesis: back to the bench
Darabi et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells
Itescu et al. New directions in strategies using cell therapy for heart disease
AU2008334036B2 (en) Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2007085745A1 (fr) Procede de culture de cellules issues du tissu adipeux et leurs applications
EP1663263B1 (fr) Utilisation de cellules issues du tissu adipeux pour induire la formation d'un reseau vasculaire fonctionnel.
Leite et al. Multipotent stem cells of the heart—do they have therapeutic promise?
Chen et al. Danhong injection enhances the therapeutic efficacy of mesenchymal stem cells in myocardial infarction by promoting angiogenesis
JP2011519574A5 (https=)
WO2014163206A1 (en) Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts
EP1934333B9 (fr) Procede d'obtention de cellules musculaires lisses humaines et leurs applications
EP3747993A1 (en) Method for producing cardiomyocytes
Norol et al. GFP-transduced CD34+ and Lin− CD34− hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct
Zhang Biological behaviour and role of endothelial progenitor cells in vascular diseases
Zweigerdt The art of cobbling a running pump—will human embryonic stem cells mend broken hearts?
Kim et al. Cell therapy with bone marrow cells for myocardial regeneration
Wu et al. Genetically modified mesenchymal stem cells for improved islet transplantation
JP2009508511A5 (https=)
WO2007047963A2 (en) Use of bone-marrow derived stem cells to treat ischemia
WO2001048150A1 (en) Cells capable of differentiating into heart muscle cells
Zhao et al. Cardiac commitment driven by MyoD expression in pericardial stem cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130919